



(51) International Patent Classification:

A61K 31/351 (2006.01) A61K 31/53 (2006.01)
A61K 31/4166 (2006.01) A61K 38/17 (2006.01)
A61K 31/4184 (2006.01) A61K 45/06 (2006.01)
A61K 31/4245 (2006.01) A61P 1/16 (2006.01)
A61K 31/427 (2006.01) A61P 3/04 (2006.01)

(21) International Application Number:

PCT/US2024/023598

(22) International Filing Date:

08 April 2024 (08.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/495,049 07 April 2023 (07.04.2023) US
63/526,362 12 July 2023 (12.07.2023) US
63/615,985 29 December 2023 (29.12.2023) US

(71) Applicant: **TERNS PHARMACEUTICALS, INC.**
[US/US]; 1065 E. Hillsdale Blvd., Suite 100, Foster City,
California 94404 (US).

(72) Inventors; and

(71) Applicants: **TEAL, Olivia D.** [US/US]; c/o Terns Pharma-
ceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster
City, California 94404 (US). **QUINN, Kevin P.** [US/US]; c/
o Terns Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite
100, Foster City, California 94404 (US).

(72) Inventors: **JONES, Christopher T.**; c/o Terns Pharmaceu-
ticals, Inc., 1065 E. Hillsdale Blvd., Suite 100, Foster City,
California 94404 (US). **JASPER, Jeffrey R.**; c/o Terns
Pharmaceuticals, Inc., 1065 E. Hillsdale Blvd., Suite 100,
Foster City, California 94404 (US).

(74) Agent: **ERLACHER, Heidi** et al.; Cooley LLP, ATTN:
IP Docketing Department, 1299 Pennsylvania Avenue NW,
Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(54) Title: COMBINATION COMPRISING A THR β TA AGONIST AND A GLP-1R AGONIST FOR USE IN TREATING A LIVER DISORDER OR A CARDIOMETABOLIC DISEASE




FIG. 2

(57) Abstract: Provided herein are combinations comprising a glucagon-like peptide-1 receptor (GLP-1R) agonist and a thyroid hormone receptor beta (THR β) agonist and methods comprising administering to a subject in need thereof such combinations.

[Continued on next page]

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*